Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Neighbourly Pharmacy Inc T.NBLY.R


Primary Symbol: T.NBLY

Neighbourly Pharmacy Inc. is a Canada-based company that operates a network of community pharmacies. The Company is an owner and operator of retail pharmacies located throughout Canada under banners such as IDA/Guardian, Pharmachoice, Pharmasave and Remedy’s RX. The Company, through its subsidiaries, owns and operates a network of retail pharmacies known as Rubicon Pharmacies (Rubicon or Rubicon Pharmacies. The Company owns and operates approximately 287 locations across seven provinces and one territory, a coast-to-coast footprint that provides scale and diversification. The Company’s pharmacies provide accessible healthcare with a personal touch. The Company also owns British Columbia-based pharmacies.


TSX:NBLY - Post by User

Post by Kanatainvestoron Oct 23, 2023 1:52pm
135 Views
Post# 35696697

Average trading price since IPO

Average trading price since IPOHere are some useful numbers to get a sense of the offer price compared to the historical trading price of NBLY up until the deal was announced:

Since June 2021 $24.38
Since start of 2022 $22.22
Since October 2022 $20.11
Since start of 2023 $19.23

Since the IPO NBLY had two secondaries ex-private placement to PCP:

October 2021: 4.87 million shares at $30.75
March 2022: 5.18 million shares at $28.95

Collectively, the buyers of the above two offering represent 45% of the shares no owned by PCP. I would imagine the biggest resistance to the deal would come from these parties, assuming they are still holding their full position. Outside of that, looking at the average trading price, PCP will probably have a much better chance closing the deal at a price above $22, or somewhere at the mid-range of TD's far value assessment. Nonehteless, my guess the lack of liquidity will compel the majority of the minority to vote for the deal even at $20.5, but a couple of dollars more should eliminate any doubt. 

Finally do keep in mind, 3.5M shares or just over 15% of the non-PCP shares have traded since the deal has been announced, the vast majority of these buyers are arbitrage buyers, as such they will certainly be voting for the deal.   


<< Previous
Bullboard Posts
Next >>